Metformin is not only approved for the treatment of type 2 diabetes but also acts to suppress the expression of GRP78-dependent autophagy and enhance the pharmacological effects of BTZ (Jagannathan et al., 2015). This evidence concerns the gene HSPA5 and type 2 diabetes mellitus.